|
|
|
|
We conduced an open-label trial of gabapentim(GBP)as therapy for paroxysmal symptoms in 21 MS patients,including trigeminal neuralgia, painful toxic spasms,dysesthetic or parethetic symptoms,and ocular ataxia. Complete resolution of symptoms or partial improvement was obtained, respectively in 14 and 4 of 18 patients who ended the study.Sustained improved with minor side effects was obtained at dosages ranging from 600 to 1200 mg/d.Our findings suggested that GBP may be effective for PS and MS and warrant further study in a double-blind placebo-controlled trial. |
|